IBRXImmunityBio, Inc.

$8B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12,000-14.3% YoY

Gross Profit

$12,000100.0% margin

Operating Income

-$25M-205208.3% margin

Net Income

-$24M-204058.3% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+50.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$25M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$250M

Total Liabilities

$32M

Stockholders' Equity

$219M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12,000	$14,000	-14.3%
Gross Profit	$12,000	$14,000	-14.3%
Operating Income	-$25M	-$24M	-1.1%
Net Income	-$24M	-$24M	-1.0%

Geographic Segments

San Diego California

$100,000100%

IBRX Q4 2017 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena